Blasts Under 20 Percent of Bone Marrow Nucleated Cells
2 clinical trials · Condition
◉ Watch Blasts Under 20 Percent of Bone Marrow Nucleated Cells
| Record | Firm | Date |
|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (NCT03801434) | William Shomali | 2019-11-15 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
Track Blasts Under 20 Percent of Bone Marrow Nucleated Cells automatically
Every clearance here is in the API, with alerts when new ones post.